Abstract 227P
Background
The Lung Immune Prognostic Index (LIPI) is a low-cost circulating biomarker based on blood lactate dehydrogenase (LDH) and derived neutrophil/leukocyte ratio (dNLR) that reflects tumor burden and harmful inflammation. This score has been validated in NSCLC as well as in other tumor types. In this study, we aimed to retrospectively analyze the clinical characteristics, and LIPI of the primary tumor at diagnosis and treatment approaches of stage 3 NSCLC patients in a single center and investigate these variables’ impact on survival.
Methods
This retrospective study included 68 stage III NSCLC patients diagnosed between September 2022 and July 2024 and followed up for at least 6 months. LIPI scores were calculated based on neutrophil (leukocyte minus neutrophil) ratio (dNLR) and lactate dehydrogenase (LDH) levels, which are biomarkers at the time of diagnosis. Demographic data, treatment modalities (surgery, chemotherapy, radiotherapy), and outcomes were recorded. Survival analyses were performed using the Kaplan-Meier method, and the effect of prognostic factors was evaluated using Cox regression analysis.
Results
Of the 68 patients, 86.8% were male and 13.2% female, with a mean age of 63.4 (± 8.7) years. Patients’ LIPI scores were: Good: 42.6% (n=29), Intermediate: 39.7% (n=27), and Poor: 17.6% (n=12). Median EFS: 17.7 months in patients with good LIPI scores, 9.4 months in patients with intermediate LIPI scores, and 5.8 months in patients with poor LIPI scores (p < 0.001). Median OS: 25.7 months in patients with good LIPI scores, not reached (NR) months in patients with intermediate LIPI scores, and 6.7 months in patients with poor LIPI scores (p < 0.001). In Cox regression analysis, the HR for EFS: 2.87 (95% CI: 1.85–4.46, p < 0.001) and HR for OS: 2.59 (95% CI: 1.40–4.78, p=0.002).
Conclusions
The LIPI score calculated at diagnosis was found to be an independent prognostic factor for overall and progression-free survival in patients with stage III NSCLC. Further studies in large patient populations are needed for routine use of the LIPI score in clinical practice and to contribute to better decision-making in patient management.
Legal entity responsible for the study
The author.
Funding
Has not received any funding
Disclosure
The author has declared no conflicts of interest.